ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva™, a class of biopharmaceuticals that improve the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target key viruses, including coronavirus, and for oncology to deliver tumor-associated antigens, and neoepitopes (expressed only by cancer cells). We show 13 historical shares outstanding datapoints in our coverage of IBRX's shares outstanding history.
Understanding the changing numbers of IBRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IBRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IBRX by allowing them to research IBRX shares outstanding history
as well as any other stock in our coverage universe. |
Free IBRX Email Alerts:
Video: Shares Outstanding Importance
